Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"H. Lundbeck AS"},{"company":"Initiator Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiator Pharma reports positive data from IPED2015 Phase IIa trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Initiator Pharma"}]

H. Lundbeck AS

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia

Details:

The decision to stop the trial is based on the results of a futility interim analysis, which concluded that the trial is unlikely to achieve statistical significance on its primary endpoint, mean change from baseline to week 12 on the Brief Negative Symptom Scale (BNSS).

Lead Product(s): Lu AF11167

Therapeutic Area: Psychiatry/Psychology Product Name: Lu AF11167

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

ASK
US

Upload
your Pipeline Activity

Initiator Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Initiator Pharma reports positive data from IPED2015 Phase IIa trial

Details:

The trial demonstrated statistically significant and clinically relevant results on key efficacy endpoints in patients with sED after a single administration of IPED2015.

Lead Product(s): IPED2015

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY